#64 Panzaru: Most Favored Nation Drug Pricing and the Transatlantic Tug-of-War | Hosted by Szilard Szelpal

In this episode of CEA Talk, host Szilárd Szelpál sits down with Dr. Emil Panzaru, Research Director at the Consumer Choice Center, to unpack one of the most controversial health and trade policies on both sides of the Atlantic: Most Favored Nation drug pricing. They discuss what MFN pricing actually means for U.S. patients, how EU regulatory reforms could reshape global access to medicines, and the trade tensions between Washington and Brussels on patents and pricing. The conversation also examines the role of pharmacy benefit managers in driving up patient costs and looks ahead to what the future may hold for innovation, access, and the global pharmaceutical market.This episode dives deep into the policy tug-of-war between affordability, innovation, and trade — and what it all means for patients, governments, and the pharmaceutical industry.Support independent journalism at CEA Magazine here:https://centraleuropeanaffairs.com/donation